A reassessment of the role of B7-1 expression in tumor rejection.

PubWeight™: 1.44‹?› | Rank: Top 5%

🔗 View Article (PMC 2192183)

Published in J Exp Med on November 01, 1995

Authors

T C Wu1, A Y Huang, E M Jaffee, H I Levitsky, D M Pardoll

Author Affiliations

1: Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21287, USA.

Articles citing this

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med (1999) 7.94

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32

Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol (1997) 2.53

B16 as a mouse model for human melanoma. Curr Protoc Immunol (2001) 1.80

Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A (2001) 1.55

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34

The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis. J Clin Invest (2000) 1.27

B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J Exp Med (2001) 1.13

Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol (2001) 0.96

Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol Med (1996) 0.95

Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One (2013) 0.94

Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci U S A (1997) 0.91

Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. Br J Cancer (2003) 0.91

Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours. Br J Cancer (1998) 0.83

In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma. World J Gastroenterol (2003) 0.82

Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol (2015) 0.81

Dysregulation of B7.2 (CD86) expression on monocytes of HIV-infected individuals is associated with altered production of IL-2. Clin Exp Immunol (1999) 0.80

Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth. Biomaterials (2015) 0.78

Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the response. Immunology (2003) 0.76

Induction of abortive and productive proliferation in resting human T lymphocytes via CD3 and CD28. Immunology (1999) 0.76

The promise and reality of cancer gene therapy. Am J Hum Genet (1997) 0.75

Regulation of NKG2D(+)CD8(+) T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism. Oncoimmunology (2016) 0.75

Articles cited by this

Biology of natural killer cells. Adv Immunol (1989) 14.77

Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol (1983) 14.36

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95

In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 10.84

IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol (1980) 10.30

CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol (1989) 7.69

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell (1992) 5.67

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30

Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science (1993) 4.45

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34

Signals and signs for lymphocyte responses. Cell (1994) 3.66

Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol (1991) 3.58

B70 antigen is a second ligand for CTLA-4 and CD28. Nature (1993) 3.57

Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science (1995) 3.19

Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med (1991) 3.08

Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science (1993) 2.78

The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J Immunol (1986) 2.48

Identification of a subset of murine natural killer cells that mediates rejection of Hh-1d but not Hh-1b bone marrow grafts. J Exp Med (1989) 2.45

Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med (1985) 2.12

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med (1994) 2.01

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med (1994) 1.93

Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer. J Clin Pathol (1981) 1.87

Murine natural killer cells and marrow graft rejection. Annu Rev Immunol (1992) 1.87

Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A (1993) 1.72

Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. Crit Rev Immunol (1991) 1.68

Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res (1992) 1.65

Molecules involved in T-cell costimulation. Curr Opin Immunol (1993) 1.62

Binding of diverse peptides to MHC class I molecules inhibits target cell lysis by activated natural killer cells. Immunity (1995) 1.58

Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer (1986) 1.48

Loss of MHC class-I expression in cervical carcinomas. Int J Cancer (1990) 1.40

Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms. Br J Cancer (1984) 1.40

Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol (1992) 1.39

CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol (1994) 1.18

Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J Immunol (1989) 1.13

Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer (1983) 1.12

HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer (1989) 1.08

HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas. Br J Cancer (1987) 1.02

Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst (1984) 0.97

Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. J Natl Cancer Inst (1983) 0.91

Multiple natural killer cell-activating signals are inhibited by major histocompatibility complex class I expression in target cells. Eur J Immunol (1994) 0.89

Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet (1988) 0.82

Articles by these authors

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03

Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000) 4.23

Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science (1989) 4.19

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98

A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature (1987) 3.96

A fixed site of DNA replication in eucaryotic cells. Cell (1980) 3.78

Molecular and cellular events of T cell development. Adv Immunol (1989) 3.50

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res (2001) 3.32

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27

Supercoiled loops and eucaryotic DNA replicaton. Cell (1980) 3.24

Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res (2000) 2.91

Deletion of self-reactive thymocytes occurs at a CD4+8+ precursor stage. Nature (1988) 2.84

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 2.81

CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med (1998) 2.69

Cell polarity: an examination of its behavioral expression and its consequences for polymorphonuclear leukocyte chemotaxis. J Cell Biol (1981) 2.64

Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci U S A (1987) 2.57

Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity (1999) 2.55

Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50

Characterization of T cell receptor gamma chain expression in a subset of murine thymocytes. Science (1986) 2.40

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27

The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A (1996) 2.24

Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 2.13

Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 2.10

Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood (2001) 2.09

Effects of cyclosporine A on T cell development and clonal deletion. Science (1988) 2.08

T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev (1987) 2.07

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med (1994) 2.01

Differential expression of two distinct T-cell receptors during thymocyte development. Nature (1987) 1.95

Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A (1998) 1.95

The fate of CD4-8- T cell receptor-alpha beta+ thymocytes. J Immunol (1991) 1.90

Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst (1995) 1.90

In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity (1996) 1.89

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res (2000) 1.86

T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74

Localization of SV40 genes within supercoiled loop domains. Nucleic Acids Res (1980) 1.68

Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther (1999) 1.63

Carrier detection in X-linked agammaglobulinemia by analysis of X-chromosome inactivation. N Engl J Med (1987) 1.63

Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res (1999) 1.56

Tumour antigens. A new look for the 1990s. Nature (1994) 1.56

Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood (2000) 1.56

CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med (2000) 1.48

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 1.48

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res (2001) 1.47

Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res (1995) 1.45

Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41

Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer (1998) 1.38

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (2010) 1.36

In vivo CD4+ T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol (2000) 1.36

Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A (1999) 1.30

Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer (2005) 1.29

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther (1999) 1.24

The relationship of the nuclear matrix to cellular structure and function. Adv Enzyme Regul (1978) 1.23

Sequence analysis of nuclear matrix associated DNA from rat liver. Exp Cell Res (1980) 1.17

Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol (1994) 1.17

Early genetic events in T cell development analyzed by in situ hybridization. J Exp Med (1987) 1.16

Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med (1996) 1.13

Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther (2001) 1.10

Tolerance and cancer: a critical issue in tumor immunology. Crit Rev Oncog (1996) 1.09

Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine (2000) 1.08

Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther (1998) 1.08

Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3. J Immunol (1988) 1.04

Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther (2001) 1.04

The unfolding story of T cell receptor gamma. FASEB J (1987) 1.04

Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res (1993) 1.03

Activation properties of T cell receptor-gamma delta hybridomas expressing diversity in both gamma- and delta-chains. J Immunol (1988) 1.03

Cancer vaccines. J Clin Oncol (1999) 0.99

Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther (1995) 0.98

Molecular mechanisms for lineage commitment in T cell development. Semin Immunol (1990) 0.98

Sound orientation behavior in cats. I. Localization of broadband noise. J Acoust Soc Am (1996) 0.98

Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys (2000) 0.98

Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol (1996) 0.97

Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol (1998) 0.94

Cyclosporin A inhibits positive selection and delays negative selection in alpha beta TCR transgenic mice. J Immunol (1994) 0.94

Hematopoietic cell transplantation in the twitcher mouse. The effects of pretransplant conditioning with graded doses of busulfan. Transplantation (1993) 0.94

Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. Blood (1991) 0.93

Passive sorting in maturing granules of AtT-20 cells: the entry and exit of salivary amylase and proline-rich protein. J Cell Biol (1997) 0.93